Across TCGA pan-cancer cohorts, TCHHL1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TCHHL1 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher TCHHL1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TCHHL1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
OV and UCEC are the cancer types where TCHHL1 Mutation most reproducibly stratifies survival.